Outcome Values for Each Subject at Baseline and 2–4 Hours After Physostigmine Injection
| fp at baseline | fp before physostigmine | fp after physostigmine* | fp at end of study | VT/fp at baseline | VT/fp after physostigmine* | BPf at baseline | BPf after physostigmine* | |||||||||||||
| Subject no. | Thal | CB | Cort | Str | Thal | CB | Cort | Str | Thal | CB | Cort | Str | Thal | CB | Cort | Str | ||||
| 1 | 32.6% | 37.0% | 36.4% | 39.2% | 151.0 | 73.9 | 54.0 | 77.8 | 140.9 | 64.7 | 49.4 | 71.9 | 131.6 | 54.5 | 34.6 | 58.4 | 121.5 | 45.3 | 30.0 | 52.5 |
| 2 | 37.0% | 36.1% | 36.5% | 37.5% | 131.4 | 25.2 | 51.3 | 70.9 | 102.9 | 20.0 | 38.4 | 56.9 | 112.0 | 5.8 | 31.9 | 51.5 | 83.5 | 0.6 | 19.0 | 37.5 |
| 3 | 35.9% | 34.7% | 32.9% | 28.6% | 129.9 | 40.3 | 51.3 | 69.0 | 111.5 | 33.0 | 42.0 | 56.9 | 110.5 | 20.9 | 31.9 | 49.6 | 92.1 | 13.6 | 22.6 | 37.5 |
| 4 | 25.8% | 25.0% | 25.9% | 34.2% | 180.5 | 75.8 | 64.9 | 93.1 | 140.2 | 58.0 | 48.1 | 74.1 | 161.1 | 56.4 | 45.5 | 73.7 | 120.8 | 38.6 | 28.7 | 54.7 |
| 5 | 33.7% | 37.4% | 44.3% | 47.3% | 125.4 | 69.4 | 49.4 | 68.5 | 81.5 | 49.6 | 34.4 | 51.7 | 106.0 | 50.0 | 30.0 | 49.1 | 62.1 | 30.2 | 15.0 | 32.3 |
| 6 | 36.6% | 35.4% | 39.3% | 111.1 | 55.6 | 40.9 | 65.1 | 111.0 | 55.4 | 40.0 | 67.8 | 91.7 | 36.2 | 21.5 | 45.7 | 91.6 | 36.0 | 20.6 | 48.4 | |
| Mean | 33.6% | 34.3% | 35.9% | 37.4% | 138.2 | 56.7 | 52.0 | 74.1 | 114.7 | 46.8 | 42.0 | 63.2 | 118.8 | 37.3 | 32.6 | 54.7 | 95.3 | 27.4 | 22.6 | 43.8 |
| SD | 4.17% | 4.65% | 6.19% | 6.87% | 24.4 | 20.4 | 7.8 | 10.22 | 22.8 | 17.0 | 5.8 | 9.2 | 24.4 | 20.4 | 7.8 | 10.2 | 22.8 | 17.0 | 5.8 | 9.2 |
↵* Value at 2–4 h after physostigmine administration, at time of greatest displacement of radioligand by acetylcholine.
CB = cerebellum; Cort = mean cortex; Str = striatum; Thal = thalamus.
Final blood sample could not be drawn for subject 6.